Savara Misses PDUFA Date as Inhaled GM-CSF Awaits Proof of Clinical Benefit
Regulatory Approvals

Savara Misses PDUFA Date as Inhaled GM-CSF Awaits Proof of Clinical Benefit

Published : 21 Nov 2026

At a Glance
IndicationAutoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Drugmolgramostim
Mechanism of ActionGM-CSF
CompanySavara Inc.
CategoryRegulatory Milestone
Sub CategoryApproval Pending
Therapeutic AreaRare Diseases & Genetics
PDUFA Target DateNovember 22, 2026
Regulatory AgencyU.S. Food and Drug Administration (FDA)
Application TypeBiologics License Application (BLA)
Review StatusOngoing, no revised action date
Drug Delivery SystemeFlow® Nebulizer System
Company StageClinical-stage

FDA Misses PDUFA Date for Savara's Molgramostim BLA

Savara Inc. announced that the U.S. Food and Drug Administration (FDA) will not meet the Prescription Drug User Fee Act (PDUFA) target action date of November 22, 2026, for the company's molgramostim inhalation solution Biologics License Application (BLA). This BLA is for the treatment of autoimmune Pulmonary Alveolar Proteinosis (PAP). The FDA's review of the application is ongoing, and the agency has not provided a revised action date. Savara's CEO expressed appreciation for the FDA’s continued efforts and looks forward to working closely to complete the review.

  • The U.S. Food and Drug Administration (FDA) has informed Savara Inc. that it will not meet the Prescription Drug User Fee Act (PDUFA) target action date of November 22, 2026, for the molgramostim inhalation solution Biologics License Application (BLA). This decision signifies a delay in the regulatory review process for molgramostim, which is intended for the treatment of autoimmune Pulmonary Alveolar Proteinosis (PAP).
  • Despite the missed PDUFA target date, the FDA's review of Savara's molgramostim BLA remains ongoing. However, the agency has not communicated any revised action date, leaving the timeline for a potential regulatory decision uncertain. Savara's Chair and CEO, Matt Pauls, reiterated the company's commitment to collaborating with the FDA to finalize the review.
  • Molgramostim inhalation solution is an investigational recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) designed to treat autoimmune PAP. This rare lung disease is characterized by autoantibodies neutralizing GM-CSF, which impairs alveolar macrophages from clearing surfactant, leading to its accumulation and subsequent respiratory symptoms. Molgramostim aims to restore GM-CSF function to address this underlying pathology.

Addressing the Unmet Needs in Autoimmune PAP Treatment

Autoimmune pulmonary alveolar proteinosis management centers on whole lung lavage (WLL) with adjunctive inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF), yet sustained control remains difficult. WLL is a widely accepted palliative treatment that does not correct myeloid cell dysfunction, and procedural practices vary widely across institutions.

  • Palliative effect without correction of underlying dysfunction: WLL clears accumulated surfactant but does not correct myeloid cell dysfunction or reverse the pathologic accumulation of surfactant, while inhaled recombinant GM-CSF restores alveolar macrophage functions including surfactant clearance.

  • High recurrence and need for repeat lavage: Recurrence is common, with one-third of patients requiring repeat lavage within 2 to 3 years, and in 7 improved cases in whom AaDO2 decreased more than 10 Torr, the median recurrence-free survival of APAP after WLL was 17.5 months.

  • Persistent autoantibody burden: The serum levels of anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) antibody temporarily decreased after unilateral WLL, but returned to previous levels (before WLL) in 7 cases.

  • Procedural complexity and periprocedural risk: WLL should only be performed in expert centers, requires general anesthesia with single-lung ventilation, and is challenging in severe hypoxaemia with partial pressure of oxygen (PaO)/fraction of inspired oxygen (FiO) <150; reported complications include termination of WLL procedure due to fluid leakage or refractory hypoxemia, bronchospasm, delayed endotracheal extubation, cardiovascular event, pneumothorax, and fever, with fever observed in 87.5% of all procedures in one series of 8 cases.

  • Limited efficacy of systemic immunologic approaches: Other treatments, such as rituximab or plasmapheresis, seem to be less efficient or ineffective; plasmapheresis with ten 1.5-L plasma exchanges lowered serum GM-CSF autoantibody level from 250 microg mL(-1) to 156 microg mL(-1) but did not improve respiratory impairment, confirming that minor reductions in serum granulocyte-macrophage colony-stimulating factor autoantibody levels from plasmapheresis are not reflected in clinical improvement.

  • Infection susceptibility and unpredictable course: The main complications of PAP are due to infections by standard pathogens (Streptococcus, Haemophilus and Enterobacteria) or opportunistic pathogens such as mycobacteria, Nocardia, Actinomyces, Aspergillus or Cryptococcus, and the clinical course of PAP is unpredictable and spontaneous improvement can occur.

Understanding Autoimmune PAP's Mechanism and Molgramostim's Role

Autoimmune pulmonary alveolar proteinosis is driven by IgG autoantibodies that block GM-CSF effect, a crucial step for macrophage maturation. High levels of neutralizing GM-CSF autoantibodies cause loss of functional granulocyte-macrophage colony-stimulating factor signaling, resulting in impaired function of alveolar macrophages and insufficient surfactant clearance by alveolar macrophages. Characterization of 21 GM-CSF autoantibodies from PAP patients found that somatic mutations critically determine their specificity for the self-antigen, with individual antibodies only partially neutralizing GM-CSF activity in vitro while a combination of three non-cross-competing antibodies completely neutralizes GM-CSF activity in vitro by sequestering the cytokine in high-molecular-weight complexes, and in vivo promotes the rapid degradation of GM-CSF-containing immune complexes in an Fc-dependent manner.

Loss of GM-CSF signaling disrupts a PPARγ-dependent macrophage lipid regulation program that normally maintains surfactant homeostasis through regulation of ABCG1. Alveolar macrophages from PAP patients are foamy, lipid-filled cells with impaired surfactant clearance and markedly reduced expression of the transcription factor peroxisome proliferator-activated receptor gamma (PPARγ) and the PPARγ-regulated ATP binding cassette lipid transporter, ABCG1, with decreased ABCG1-mediated cholesterol efflux to HDL. Lysosomal phospholipase A2 (LPLA2), a key enzyme in surfactant degradation, mRNA expression was severely deficient in PAP patients pre-treatment, and reduction in GM-CSF autoantibodies by rituximab therapy increased mean PPARγ and ABCG1 mRNA expression 2.8 and 5.3-fold respectively and LPLA2 mRNA expression 2.8-fold, with decreased Oil Red O intensity indicating reduced intracellular lipid while extracellular free cholesterol increased in BAL fluid and total protein and Surfactant protein A were significantly decreased in the BAL fluid post therapy.

Unlike many autoimmune diseases with distinct genetic association to HLA alleles, autoimmune PAP lacks an HLA association. Analysis of amino acid and allele associations for HLA-A, B, C, DRB1, DQB1, DPB1, DRB3, DRB4 and DRB5 in 41 autoimmune PAP patients compared to 1000 ethnic-matched controls did not find any HLA association with autoimmune PAP. The resulting cellular pathology is accumulation of pulmonary surfactant in alveolar macrophages and alveoli and accumulation of surfactant-derived lipoproteins within pulmonary alveolar macrophages and alveoli, resulting in respiratory impairment, respiratory insufficiency and an increased risk of opportunistic infections.

We are experiencing a brief delay in retrieving the requested information. Please retry after a short interval. Ensuring the accuracy of information remains our top priority.

Frequently Asked Questions

What are the primary clinical challenges in managing Autoimmune Pulmonary Alveolar Proteinosis?
Autoimmune PAP presents significant challenges due to its progressive nature and the impact of surfactant accumulation on gas exchange. Current management often involves invasive procedures like whole lung lavage, which provides temporary relief but does not address the underlying immunological defect. Patients frequently experience recurrent symptoms and impaired quality of life.
What is the mechanism of action of molgramostim in Autoimmune Pulmonary Alveolar Proteinosis?
Molgramostim is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). In Autoimmune PAP, neutralizing autoantibodies against GM-CSF lead to functional deficiency of this cytokine. Molgramostim aims to overcome this deficiency, restoring GM-CSF signaling essential for the maturation and function of alveolar macrophages.
How does targeting GM-CSF deficiency with molgramostim address the pathophysiology of Autoimmune PAP?
By providing exogenous GM-CSF, molgramostim directly counteracts the functional deficiency caused by autoantibodies. This restoration of GM-CSF signaling is crucial for enabling alveolar macrophages to effectively clear the lipoproteinaceous material accumulating in the alveoli. Improved macrophage function helps resolve the proteinosis and enhances pulmonary gas exchange.
What is the significance of developing targeted therapies like molgramostim for rare lung diseases such as Autoimmune PAP?
Developing targeted therapies for rare lung diseases addresses critical unmet medical needs in patient populations with limited treatment options. These therapies often focus on the underlying disease mechanisms, offering the potential for more effective and less invasive interventions. Such advancements can significantly improve long-term outcomes and quality of life for patients with conditions like Autoimmune PAP.

References

  1. [1] Jouneau S, Ménard C et al.. Pulmonary alveolar proteinosis. Respirology (Carlton, Vic.). 2020 Aug. 32363736
  2. [2] Xu X, Qiu H et al.. Association between one-session bilateral whole-lung lavage and periprocedural complications in patients with pulmonary alveolar proteinosis: a retrospective cohort study. Orphanet journal of rare diseases. 2023 Apr 20. 37081515
  3. [3] Malur A, Kavuru MS et al.. Rituximab therapy in pulmonary alveolar proteinosis improves alveolar macrophage lipid homeostasis. Respiratory research. 2012 Jun 14. 22697800
  4. [4] Tanaka T, Motoi N et al.. Adult-onset hereditary pulmonary alveolar proteinosis caused by a single-base deletion in CSF2RB. Journal of medical genetics. 2011 Mar. 21075760
  5. [5] Garber B, Albores J et al.. A plasmapheresis protocol for refractory pulmonary alveolar proteinosis. Lung. 2015 Apr. 25557091
  6. [6] Jouneau S, Chauvin P et al.. Pharmacotherapy for Autoimmune Pulmonary Alveolar Proteinosis. Drugs. 2025 Oct. 40866780
  7. [7] Sugimoto C, Arai T et al.. [Multidisciplinary assessment of effects, safety and procedure of whole lung lavage for 8 patients with autoimmune pulmonary alveolar proteinosis]. Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society. 2011 Aug. 21894771
  8. [8] Ataya A, Mathavan A et al.. Whole Lung Lavage in Pulmonary Alveolar Proteinosis. Chest. 2026 Feb. 41072904
  9. [9] Wu XK, Lin Q. Pulmonary alveolar proteinosis complicated with nocardiosis: A case report and review of the literature. World journal of clinical cases. 2021 Apr 26. 33969072
  10. [10] Ben-Dov I, Segel MJ. Autoimmune pulmonary alveolar proteinosis: clinical course and diagnostic criteria. Autoimmunity reviews. 2014 Apr-May. 24424195
  11. [11] Zhen G, Li D et al.. Granulocyte-Macrophage Colony-Stimulating Factor Inhalation Therapy for Severe Pulmonary Alveolar Proteinosis. American journal of therapeutics. 2020 Mar 25. 31513019
  12. [12] Kobayashi H, Kanoh S et al.. Serum surfactant protein-A, but not surfactant protein-D or KL-6, can predict preclinical lung damage induced by smoking. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals. 2008 Jun. 18595202
  13. [13] Kelly A, McCarthy C. Pulmonary Alveolar Proteinosis Syndrome. Seminars in respiratory and critical care medicine. 2020 Apr. 32279299
  14. [14] Braun AT, Merlo CA. Cystic fibrosis lung transplantation. Current opinion in pulmonary medicine. 2011 Nov. 21897255
  15. [15] Martinez-Moczygemba M, Huston DP. Immune dysregulation in the pathogenesis of pulmonary alveolar proteinosis. Current allergy and asthma reports. 2010 Sep. 20623372
  16. [16] Hwang JA, Song JH et al.. Clinical significance of cigarette smoking and dust exposure in pulmonary alveolar proteinosis: a Korean national survey. BMC pulmonary medicine. 2017 Nov 21. 29162083
  17. [17] Campo I, Carey BC et al.. Inhaled recombinant GM-CSF reduces the need for whole lung lavage and improves gas exchange in autoimmune pulmonary alveolar proteinosis patients. The European respiratory journal. 2024 Jan. 37973175
  18. [18] Khanna A, Chaudhary N. Staged whole lung lavage in severe pulmonary alveolar proteinosis-Anaesthetic strategies for one-lung ventilation: A case report. Indian journal of anaesthesia. 2026 Jul. 42500632
  19. [19] Li Q, Wu J et al.. ECMO-assisted whole lung lavage combined with GM-CSF inhalation for severe pulmonary alveolar proteinosis: a comparative cohort study. Immunobiology. 2026 Sep. 42691524
  20. [20] Lopez-Rodriguez E, Gay-Jordi G et al.. Lung surfactant metabolism: early in life, early in disease and target in cell therapy. Cell and tissue research. 2017 Mar. 27783217

Contact Us

📍

Address

350 Springfield Avenue,
Suite #200 Summit, NJ 07901

✉️

For General Inquiry

info@pienomial.com

Related Posts